Therapeutic effect of nasal corticosteroids combined with nasal antihistamine on vasomotor rhinitis
-
摘要: 目的: 观察鼻用糖皮质激素联合鼻用抗组胺药治疗血管运动性鼻炎的临床疗效。方法: 随机将120例血管运动性鼻炎患者分为联合用药组、布地奈德组及氮卓斯汀组,每组40例。联合用药组给予鼻用糖皮质激素联合鼻用抗组胺药喷鼻,布地奈德组只给予鼻用糖皮质激素(布地奈德鼻喷雾剂)喷鼻,氮卓斯汀组只给予鼻用抗组胺药(盐酸氮卓斯汀鼻喷剂)喷鼻,疗程8周,比较3组患者治疗后临床疗效。结果: ①视觉模拟量表(VAS)评分:治疗后3组患者各自鼻部症状VAS评分均明显降低,与治疗前相比,差异有统计学意义(P<0.05);联合用药组患者鼻部症状VAS评分均较布地奈德组及氮卓斯汀组低,差异有统计学意义(P<0.05);治疗后,鼻部症状中鼻塞症状VAS评分布地奈德组比氮卓斯汀组低,差异有统计学意义(P<0.05),余3种鼻部症状VAS评分及VAS总评分治疗后布地奈德组与氮卓斯汀组差异无统计学意义。②生活质量(SF-12v2)评分:治疗后3组患者生活质量评分均明显升高,与治疗前相比,差异有统计学意义(P<0.05);联合用药组患者SF-12v2评分均较布地奈德组及氮卓斯汀组高,差异有统计学意义(P<0.05);治疗后布地奈德组与氮卓斯汀组差异无统计学意义(P>0.05)。③疗效:联合用药组患者显效率(47.50%)及总有效率(90.00%)分别与布地奈德组(30.00%,75.00%)及氮卓斯汀组(27.50%,70.00%)比较,差异均有统计学意义(P<0.05);治疗后布地奈德组与氮卓斯汀组疗效差异无统计学意义(P>0.05)。结论: 鼻用糖皮质激素和鼻用抗组胺药均可有效缓解血管运动性鼻炎的鼻部症状并能提高患者的生活质量;鼻用糖皮质激素缓解鼻塞的效果要优于鼻用抗组胺药;鼻用糖皮质激素和鼻用抗组胺药联用的效果优于单独用药。Abstract: Objective: To observe the clinical efficacy of nasal corticosteroids combined with nasal antihistamine in the treatment of vasomotor rhinitis.Method: One hundred and twenty vasomotor rhinitis patients were randomly divided into three groups including budesonide group, azelastine group, and budesonide and azelastine group with 40 cases in each. Nasal spray with nasal corticosteroids and nasal antihistamines was applied for combined treatment group, while the patients in budesonide group and azelastine group were given only nasal corticosteroids and nasal antihistamines, respectively. The course lasted 8 weeks, and the clinical efficacy was evaluated with the visual analogue scale (VAS) score and SF-12v2 score.Result: VAS score of the peripheral nasal symptoms of the three groups was significantly decreased after treatment, and the difference was statistically significant compared with that before treatment (P<0.05). The visual analogue scale of nasal symptoms in the combined treatment group was significantly lower than that in the budesonide group and the azelastine group. There was no statistically significant difference between the budesonide group and the azelastine group after the treatment on the VAS of the three nasal symptoms. However, compared with before treatment, the difference was statistically significant (P<0.05).The visual analogue scale of nasal symptoms in the combined treatment group was higher than that in the budesonide group and the azelastine group, and the difference was statistically significant (P<0.05). After treatment, there was no significant difference between budesonide group and azelastine group (P>0.05). At the same time, the patients in the combined treatment group showed significant efficiency of 47.50% and total efficiency of 90.00%, which were statistically significant compared with budesonide group (30.00%,75.00%) and azelastine group (27.50, 70.00%), respectively (P<0.05). But there was no significant difference between budesonide group and azelastine group (P>0.05).Conclusion: Nasal corticosteroids and nasal antihistamine can effectively relieve the nasal symptoms of vasomotor rhinitis and improve the quality of life of patients. The effect of nasal corticosteroids was better than that of nasal antihistamine. The effect of nasal corticosteroids combined with nasal antihistamine was superior to that of single drug.
-
Key words:
- nasal corticosteroids /
- nasal antihistamine /
- vasomotor rhinitis /
- combination
-
-
[1] LAL D, COREY J P.Vasomotor rhinitis update[J].Curr Opin Otolaryngol Head Neck Surg, 2004, 12:243-247.
[2] SHAH R, MCGRATH K G.Chapter 6:Nonallergic rhinitis[J].Allergy Asthma Proc, 2012, 33 Suppl 1:19-21.
[3] SCARUPA M D, KALINER M A.Nonallergic rhinitis, with a focus on vasomotor rhinitis:clinical importance, differential diagnosis, and effective treatment recommendations[J].World Allergy Organ J, 2009, 2:20-25.
[4] KALINER M A.Classification of Nonallergic Rhinitis Syndromes With a Focus on Vasomotor Rhinitis, Proposed to be Known henceforth as Nonallergic Rhinopathy[J].World Allergy Organ J, 2009, 2:98-101.
[5] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组.血管运动性鼻炎诊断和治疗建议 (2013年, 苏州)[J].中华耳鼻咽喉头颈外科杂志, 2013, 48 (11):884-885.
[6] TRAN N P, VICKERY J, BLAISS M S.Management of rhinitis:allergic and non-allergic[J].Allergy Asthma Immunol Res, 2011, 3:148-156.
[7] LAM C L, TSE E Y, GANDEK B.Is the standard SF-12health survey valid and equivalent for a Chinesepopulation[J]?Qual Life Res, 2005, 14:539-547.
[8] SYNNERSTAD B, LINDQVIST N.A clinical comparison of intranasal budesonide with beclomethasone dipropionate for perennial non-allergic rhinitis:a 12month study[J].Br J Clin Pract, 1996, 50:363-366.
[9] RINNE J, SIMOLA M, MALMBERG H, et al.Early treatment of perennial rhinitis with budesonide or cetirizine and its effect on long-term outcome[J].J Allergy Clin Immunol, 2002, 109:426-432.
[10] 庄惠文, 文卫平.局部糖皮质激素治疗慢性非变应性鼻炎的疗效分析[J].临床耳鼻咽喉科杂志, 2006, 20:67-69.
[11] MYGIND N, ANDERSSON M.Topical glucocorticosteroids in rhinitis:clinical aspects[J].Acta Otolaryngol, 2006, 126:1022-1029.
[12] BANOV C H, LIEBERMAN P, VASOMOTOR RHI-NITIS STUDY GROUPS.Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis[J].Ann Allergy Asthma Immunol, 2001, 86:28-35.
[13] CIPRANDI G.Treatment of nonallergic perennial rhinitis[J].Allergy, 2004, 59 Suppl 76:16-22.
[14] GARAY R.Mechanisms of vasomotor rhinitis[J].Allergy, 2004, 59 Suppl 76:4-9.
[15] VAN RIJSWIJK J B, BLOM H M, FOKKENS W J.Idiopathic rhinitis, the ongoingquest[J].Allergy, 2005, 60:1471-1481.
[16] FOKKENS W J.Thoughts on the pathophysiology of nonallergic rhinitis[J].Curr Allergy Asthma Rep, 2002, 2:203-209.
[17] 左可军, SAIL G A, 许庚, 等.糠酸莫米松鼻喷剂治疗非变应性鼻炎的多中心临床研究[J].中华耳鼻咽喉头颈外科杂志, 2010, 45 (12):982-987.
-
计量
- 文章访问数: 245
- PDF下载数: 102
- 施引文献: 0
下载: